drug
CT-868
Phase 2updated 3mo agoby F. Hoffmann-La Roche Ltd
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying CT-868
- phase2A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- phase2A Study of CT-868 in Type 1 Diabetes Mellitus
- phase1A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
- phase1A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
News(2)
- Roche cans one Carmot obesity asset as another shows best-in-class potentialAcmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…biospace · 21d ago
- Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesRoche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…fiercebiotech · 23d ago
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that